Coramitug

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameCoramitug
Drug Alias NameNNC6019-0001NNC-6019PRX-004NN6019
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cellular phagocytosis (ADCP) effectsAmyloid inhibitorsTransthyretin modulators
TargetsAmyloidTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisCardiomyopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[21
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Inactive CompaniesProthena Biosciences Ltd
Active IndicationsTransthyretin amyloidosisCardiomyopathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A